Impact of HPV infection on the clinical outcome of p-CAIR trial in head and neck cancer

Eur Arch Otorhinolaryngol. 2011 May;268(5):721-6. doi: 10.1007/s00405-010-1396-7. Epub 2010 Oct 12.

Abstract

The purpose of the study was to analyse the influence of HPV infection on the outcome of a randomized clinical trial of conventional (CF) versus 7-days-a-week postoperative radiotherapy (p-CAIR) for squamous cell cancer of the head and neck (SCCHN). Between 2001 and 2004, 279 patients with high-risk SCC of the larynx or cancer of the oral cavity/oropharynx were randomized to receive 63 Gy in fractions of 1.8 Gy given 5 days a week or 7 days a week (Radiother Oncol 87:155-163, 2008). The presence of HPV DNA in 131 archival paraffin blocks was assessed with multiplex quantitative real-time PCR using five consensus primers for the conservative L1 region and molecular beacon probes targeting 14 high-risk HPV subtypes. Following the RT-PCR procedure, we could determine the presence and type of HPV16, HPV18 and the other 12 less frequent oncogenic subtypes. Out of 131 samples, 9 were positive for HPV infection (6.9%), all of them with HPV16 subtype. None of the 65 laryngeal tumours was HPV positive. The 5-year LRC in HPV-positive patients was 100%, compared to 58% in the HPV-negative group (p = 0.02, log-rank test). Amongst 122 patients with HPV-negative tumours, 5-year LRC was 50.3% in p-CF versus 65.2 in p-CAIR (p = 0.37). HPV infection was associated with low expression of EGFR and cyclin D. This study demonstrates a favourable outcome for HPV-positive patients with SCCHN treated with postoperative radiotherapy. While considering the small number of HPV+ tumours, the data set can be considered as hypothesis generating only, the outcome raises new questions on the necessity of aggressive postoperative treatment in HPV+ patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / metabolism
  • Carcinoma, Squamous Cell / metabolism
  • Carcinoma, Squamous Cell / radiotherapy*
  • Carcinoma, Squamous Cell / virology
  • DNA, Viral / analysis
  • Dose Fractionation, Radiation
  • Female
  • Head and Neck Neoplasms / metabolism
  • Head and Neck Neoplasms / radiotherapy*
  • Head and Neck Neoplasms / virology
  • Human papillomavirus 16 / isolation & purification
  • Humans
  • Laryngeal Neoplasms / radiotherapy
  • Laryngeal Neoplasms / virology
  • Male
  • Middle Aged
  • Mouth Neoplasms / radiotherapy
  • Mouth Neoplasms / virology
  • Neoplasm Recurrence, Local
  • Oropharyngeal Neoplasms / radiotherapy
  • Oropharyngeal Neoplasms / virology
  • Papillomavirus Infections / complications*
  • Papillomavirus Infections / diagnosis
  • Radiotherapy Dosage
  • Randomized Controlled Trials as Topic
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • DNA, Viral